RHHBY - Oncolytics reports positive safety data in phase 1/2 pancreatic cancer group

Oncolytics Biotech (NASDAQ:ONCY) said no safety concerns were seen in the three-patient pancreatic cancer group of a phase 1/2 GOBLET study evaluating pelareorep in combination with Roche's (OTCQX:RHHBY) atezolizumab. Data Safety Monitoring Board recommended the study proceed as planned. The trial, which is being managed by Germany-based academic cooperative medical oncology group AIO, is evaluating the drug combination in patients with metastatic pancreatic, metastatic colorectal, and advanced anal cancers. The safety run-in for the trial's third-line metastatic colorectal cancer cohort remains ongoing. The trial is ongoing and is expected to enroll patients at 14 clinical trial sites across Germany. The study's pancreatic cancer cohort extends previously reported clinical data showing anti-cancer activity of pelareorep combined with checkpoint inhibition in pancreatic cancer patients who progressed after first-line treatment. The company added that it also builds on prior early clinical data which showed a greater than 80% increase in median progression-free survival in patients

For further details see:

Oncolytics reports positive safety data in phase 1/2 pancreatic cancer group